Compare General Motors Company (GM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Travere Therapeutics Inc. Common Stock — how do they compare? General Motors Company trades at $83.03 (market cap $73.71B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: General Motors Company is far larger — about 15.1× Travere Therapeutics Inc. Common Stock's market cap, and General Motors Company pays a 0.86% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GM | TVTX | |
|---|---|---|
Market Cap | $73.71B | $4.88B |
Volume | 6,224,747 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $67.52 |
52-Week Low | $57.34 | $26.79 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $176.68B | $5.01B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $83.05, up 0.83% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, though Q3 2026 results are pending. Valuation metrics appear reasonable with P/S of 0.42 and P/B of 1.19, while profitability remains modest with 1.05% net margin. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 vehicle sales declined 5.5%.
GM faces near-term headwinds from declining sales and margin pressure, but analyst consensus remains bullish with a $102.33 price target representing 23% upside. The company benefits from regulatory savings and EV partnerships, though execution risks and market share erosion require monitoring. Cash flow stability and dividend payments provide shareholder support amid industry transition challenges.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
